Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Implementing an Evidence-based Alcohol Use and Sexual Risk Intervention in Young Adult Homeless Service Settings

6. November 2026 aktualisiert von: Graham DiGuiseppi, RAND

The goal of this clinical trial is to learn if AWARE-a brief, 4-session group program based on motivational interviewing-reduces alcohol and other drug use and sexual risk behavior among young adults experiencing homelessness (ages 18-25). The study will also learn how well AWARE can be delivered in real-world drop-in center settings and what it would take to keep the program running long-term.

The main questions it aims to answer are:

  • Does AWARE reduce the frequency, quantity, and consequences of alcohol use more than services as usual?
  • Does AWARE reduce sexual risk behavior (condomless sex with primary and casual partners, number of sexual partners, and alcohol or other drug use during sexual activity)?
  • How consistently and well can AWARE be delivered at community drop-in centers?

Researchers will compare AWARE to services as usual at three drop-in centers in Los Angeles and Pittsburgh to see if AWARE works to better.

Participants will:

  • Attend up to 4 group sessions of AWARE or continue receiving usual services at their drop-in center
  • Complete surveys about their alcohol and drug use, sexual behavior, and health at study enrollment, and 3 and 6 month follow-ups.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Young adults experiencing homelessness (YAEH) are disproportionately affected by alcohol and other drug (AOD) use and sexual risk behavior, yet drop-in centers serving this population have limited access to brief, evidence-based programs that address both. AWARE is a 4-session group intervention grounded in motivational interviewing (MI) that targets AOD use and sexual risk behavior among 18-25 year olds experiencing homelessness. The program integrates education, skills building, and normative feedback in an interactive group format, incorporating components shown to be effective with homeless youth and other at-risk populations: enhancing protective factors, targeting multiple risk behaviors together, using active learning techniques, reinforcing skills, and delivering information in a non-judgmental manner. Sessions address HIV/STI knowledge and partner risk evaluation (Session 1), identifying and managing triggers for sexual risk behavior (Session 2), weighing the pros and cons of substance use and building strategies to reduce harm (Session 3), and understanding how AOD use affects brain functioning and behavior (Session 4). The brief format and group delivery model were designed to fit the service realities of drop-in centers, where YAEH may engage sporadically and staff capacity is limited.

The study design is a hybrid type 1 effectiveness-implementation study in which we will test the effectiveness of AWARE on young adult health outcomes, while collecting contextual data on implementation and sustainability of the intervention. The effectiveness study will follow a group-randomized design in which young adults receiving services at three drop-in centers will either be in the intervention condition (N = 180) or a services as usual control condition (N = 180). Young adult participants will complete surveys measuring primary and secondary outcomes at baseline, and follow-up surveys at 3- and 6-months post-baseline. The group-randomized trial will have crossover conditions and groups to avoid problems of power reduction and contamination associated with conventional group randomization. The unit of analysis will be the individual, but individuals will be assigned to groups based on where they receive services at a given time. The field period in each condition will be divided into four 22-week phases. The three drop-in centers will alternate serving as the "intervention site" or the "control site," with each center having two intervention phases and two control phases. The first 16 weeks of each phase involves delivering AWARE (intervention sites) or surveying participants at the control sites. Sixteen weeks was chosen to repeat the four-session AWARE program four times, allowing YAEH several opportunities to attend all sessions. The remaining six weeks of each phase is an inactive "wash out" period to allow for the recruitment of a new cohort and reduce the likelihood of contamination across conditions.

In addition to testing effectiveness, this study will assess how consistently and with what quality AWARE is delivered across sites and phases (implementation outcomes), and what organizational and fiscal conditions would support long-term sustainment. Fidelity to the AWARE protocol and MI will be assessed by audio recording sessions and rating them using an adherence checklist. Participant perspectives on intervention quality will be captured at the 3-month follow-up via item measuring therapeutic alliance and MI-consistent facilitator behaviors. Sustainment will be examined through interviews with policy actors and site leaders to identify barriers and facilitators to continued adoption beyond the study period.

Studientyp

Interventionell

Einschreibung (Geschätzt)

360

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Marylou Gilbert
  • Telefonnummer: 6007 310-393-0411
  • E-Mail: marylou@rand.org

Studienorte

    • California
      • Los Angeles, California, Vereinigte Staaten, 90028
      • Venice, California, Vereinigte Staaten, 90291
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15222
        • 412 Youth Zone
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 25 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • aged 18-25 years
  • receiving services at the drop-in center
  • plans to stay in the geographic area for the next month
  • English speaking

Exclusion Criteria:

  • Observed cognitive impairment during enrollment

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: AWARE condition

AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback. Participants will have access to all usual care services while receiving AWARE.

AWARE is a brief (four-session) group counseling intervention that uses motivational interviewing and psychoeducation to address hazardous alcohol use and sexual risk behaviors. AWARE was developed with input from young adults experiencing homelessness and service providers and has shown to be feasible, acceptable, and efficacious when delivered in young adult homeless service settings. AWARE sessions are 45-minutes in length and delivered by one to two facilitators who receive training on the AWARE protocol and motivational interviewing. AWARE sessions provide normative feedback about alcohol use, and education about sexual risk behaviors and sexually transmitted infections. AWARE is designed to be collaborative and strengths-based, helping young adults identify and plan for high-risk situations and develop effective coping strategies to reduce the likelihood of alcohol-related negative consequences and sexual risk behaviors.

Kein Eingriff: Standard care condition

Participants in the Standard Care condition have access to "usual care" at the drop-in center where the study is being conducted.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Alcohol use frequency
Zeitfenster: Baseline, 3 months, and 6 months follow-up

The number of alcohol use days (any alcohol use) and the number of binge drinking days (5+ drinks) in the past 30 days

Baseline, 3 months, and 6 months follow-up
Alcohol use quantity
Zeitfenster: Baseline, 3 months, and 6 months follow-up

The typical number of drinks consumed on drinking days, and the maximum number of drinks consumed on drinking days in the past 30 days

Baseline, 3 months, and 6 months follow-up
Alcohol use consequences
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Number of alcohol consequences in the past 30 days, assessed by the Brief Young Adult Alcohol Consequences Questionnaire (BYAACQ)

Baseline, 3 months, and 6 months follow-up

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Other drug use frequency
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Number of days of other drug use besides alcohol (cannabis, stimulants, opioids, sedatives/barbiturates, hallucinogens, cigarette and vape use) in the past 30 days.

Baseline, 3 months, and 6 months follow-up
Cannabis use quantity
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Amount of flower/bud consumed (in grams) on a typical cannabis use day

Baseline, 3 months, and 6 months follow-up
Cannabis use consequences
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Number of cannabis use consequences in the past 30 days, measured by the Brief-Marijuana Consequences Questionnaire (B-MACQ)

Baseline, 3 months, and 6 months follow-up
Substance use disorder
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Probable substance use disorder, measured with the Global Appraisal of Individual Needs Short Screener (GAIN-SS)

Baseline, 3 months, and 6 months follow-up
Number of sexual partners
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Number of oral, vaginal and anal sex partners in the past 3 months. Primary and casual sex partners will be reported separately.

Baseline, 3 months, and 6 months follow-up
Condom use
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Percentage of oral, vaginal, and anal sex events in which a condom was used in the past 3 months, assessed separately for primary and casual partners

Baseline, 3 months, and 6 months follow-up
Alcohol or other drug use during sexual activity
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Frequency of alcohol or other drug use before or during sex in the past 3 months (0=Never to 4=Every time), with primary and casual partners

Baseline, 3 months, and 6 months follow-up
Perceived importance of condom use
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Importance of increasing condom use during sex, or remaining a consistent condom user, measured on a scale from 0 (not at all important) to 10 (extremely important).

Baseline, 3 months, and 6 months follow-up
Condom use self-efficacy
Zeitfenster: Baseline, 3 months, and 6 months follow-up

Self-efficacy to use a condom correctly and consistently and to discuss condom use with partners (from "not at all sure" to "very sure"), assessed using 8-items from a scale by Brafford and Beck (1991)

Baseline, 3 months, and 6 months follow-up

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Graham DiGuiseppi, RAND
  • Hauptermittler: Ariella Korn, RAND

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. April 2027

Primärer Abschluss (Geschätzt)

30. September 2029

Studienabschluss (Geschätzt)

30. September 2029

Studienanmeldedaten

Zuerst eingereicht

6. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. November 2026

Zuerst gepostet (Tatsächlich)

12. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • R01AA033407 (US NIH Stipendium/Vertrag)
  • HLPHL029 (Andere Kennung: RAND)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Qualitative data to be shared include de-identified transcripts generated from staff focus groups and interviews with policy actors. Data will be made available to researchers for secondary analysis or replication of study findings. Transcripts will be de-identified, and sites will be referred to as Site 1, Site 2, and Site 3.

Quantitative data to be shared include de-identified, aggregate survey data to be made available for secondary analysis or replication of study findings. A separate ASCII (csv) data file will be created for young adult demographic and health outcomes (Aim 1), cost and cost-effectiveness data (Aim 1), participant reach and acceptability (Aim 2), AWARE fidelity ratings (Aim 2), and implementation outcomes (Aim 2).

IPD-Sharing-Zeitrahmen

We will deposit study data in the National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) repository starting 12 months after the award begins. Study protocols, metadata, and de-identified data sets that are ready for public use will be submitted semi-annually (twice per year). Clinical trial data will be shared after the clinical trial is completed. Final project data will be made available at time of manuscript publication, or within 12 months following the project end date, whichever comes first.

IPD-Sharing-Zugriffskriterien

Data will be findable for the research community through the NIAAADA. The study will be findable and identifiable using unique URL links. Links to public access files will be shared in all peer-reviewed publications.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .